Anavex Life Sciences annual ebitda
2010
2011
2012
2013
2014
Anavex Life Sciences's calculated EBITDA was −$3.0M for fiscal 2014.
View full Anavex Life Sciences company overview| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2014 | 2014-09-30 | −$3.0M | −$831,416 | — |
| 2013 | 2013-09-30 | −$2.1M | $2.2M | — |
| 2012 | 2012-09-30 | −$4.3M | $1.9M | — |
| 2011 | 2011-09-30 | −$6.2M | −$531,567 | — |
| 2010 | 2010-09-30 | −$5.6M | — | — |
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2015 | 2015-06-30 | −$1.5M | −$514,071 | — |
| Q2 2015 | 2015-03-31 | −$858,090 | $162,885 | — |
| Q1 2015 | 2014-12-31 | −$770,429 | −$461,013 | — |
| Q4 2014 | 2014-09-30 | −$639,175 | $829,232 | — |
| Q3 2014 | 2014-06-30 | −$998,641 | −$872,659 | — |
| Q2 2014 | 2014-03-31 | −$1.0M | −$893,975 | — |
| Q1 2014 | 2013-12-31 | −$309,416 | $105,986 | — |
| Q4 2013 | 2013-09-30 | −$1.5M | −$829,516 | — |
| Q3 2013 | 2013-06-30 | −$125,982 | $571,466 | — |
| Q2 2013 | 2013-03-31 | −$127,000 | $668,141 | — |
| Q1 2013 | 2012-12-31 | −$415,402 | $1.8M | — |
| Q4 2012 | 2012-09-30 | −$638,891 | $587,301 | — |
| Q3 2012 | 2012-06-30 | −$697,448 | $939,313 | — |
| Q2 2012 | 2012-03-31 | −$795,141 | $1.2M | — |
| Q1 2012 | 2011-12-31 | −$2.2M | −$819,499 | — |
| Q4 2011 | 2011-09-30 | −$1.2M | $76,482 | — |
| Q3 2011 | 2011-06-30 | −$1.6M | — | — |
| Q2 2011 | 2011-03-31 | −$1.9M | — | — |
| Q1 2011 | 2010-12-31 | −$1.4M | — | — |
| Q3 2010 | 2010-06-30 | −$1.3M | — | — |
Across the available reported history, Anavex Life Sciences's ebitda decreased from −$2.1M to −$3.0M, a change of −$831,416. The latest reported quarter, Q3 2015, shows −$1.5M.
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anavex Life Sciences filings at SEC.gov ↗